Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SH2 domain-containing protein 1A (abbreviated SH2D1A; also known as SLAM-associated protein, SAP) is a cytoplasmic adaptor protein containing an SH2 domain, mainly expressed in lymphocytes[1][2][4]. It plays a critical role in the immune system by regulating signal transduction from signaling lymphocytic activation molecule (SLAM) family receptors and controlling lymphocyte activation, particularly T, B, and natural killer (NK) cells[2][4]. SH2D1A is essential for normal immune cell development and the induction of apoptosis in lymphocytes when they are no longer needed[2][4]. Mutations in the SH2D1A gene are the cause of X-linked lymphoproliferative disease (XLP or Duncan disease), resulting in an abnormal or absent protein that leads to severe immunodeficiency, heightened susceptibility to Epstein-Barr virus infection, and a strong predisposition to lymphoma and other immune dysregulation conditions[1][2][4][7]. SH2D1A works as a key modulator or inhibitor of SLAM family receptor signaling, and its absence disrupts the regulation of cytotoxic lymphocytes and NKT cell development[1][2][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SH2 domain-containing protein 1A (SH2D1A).